23:16 , Nov 2, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; melanoma Mouse studies suggest increasing expression of ID2 in dendritic cells (DCs) could improve the antitumor efficacy of DC vaccines for cancer. In a mouse model of melanoma, intratumoral injection of DCs overexpressing vector-encoded...
07:00 , Nov 1, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample and mouse studies suggest promoting ID2 expression or inhibiting TCF4 could help treat PGC-1α-deficient metastatic melanoma. In primary tumor samples from 68 melanoma patients, invasive tumor pathology was associated with low levels...
07:00 , Oct 27, 2016 |  BC Innovations  |  Targets & Mechanisms

T cell gas, tumor brake

  A trio of studies has converged on a common pathway, headed by the PPAR co-activator PGC-1α, to fight cancer and chronic infections by manipulating either T cell immunotherapies or the tumors themselves. While the findings...
07:00 , Sep 9, 2002 |  BC Week In Review  |  Company News

AngioGenex, Albert Einstein College of Medicine deal

The medical school granted AngioGenex exclusive worldwide rights to its Id2 gene IP, for use in developing diagnostics and therapeutics for childhood cancers of the nervous system. AngioGenex Inc., New York, N.Y.   Albert Einstein College...